Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC).

The study is expected to recruit approximately 60 patients in the United States.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.